SOLASCURE Ltd (SolasCure), a biotechnology company developing a hydrogel containing a recombinant enzyme derived from maggots which aims to accelerate wound debridement, has announced the completion of its GBP 10.9m (c. USD 13.3m) Series B investment round. The funding round was led by Seneca Partners and also included industry veterans, institutional venture and strategic investors, including BRAIN Biotech AG, EVA Pharma, Jonathan Milner, and Wealth Club.
The principles of maggot therapy and its role in contemporary wound care nursingtimes.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nursingtimes.net Daily Mail and Mail on Sunday newspapers.